Jasper Therapeutics, Inc. (JSPR) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing biologic agents for immunologically-driven disorders. The company operates as a single segment and is headquartered in Redwood City, California. As of the filing date, the company has incurred significant losses and negative cash flows since inception, raising substantial doubt about its ability to continue as a going concern without additional financing.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3.9) million | $(48.0) million |
| Operating Expenses | $20.2 million | $48.9 million |
| Cash and Cash Equivalents (End of Period) | $7.3 million | $28.7 million |
| Net Cash Used in Operating Activities | $(21.5) million | $(38.3) million |
| Accumulated Deficit | $(320.6) million | $(288.8) million |
| Warrant Liability | $2.5 million | $16.2 million |
Note: The company has no revenue from product sales. Net loss for the six months ended June 30, 2026, was significantly reduced by a $13.6 million gain from the change in fair value of warrant liability and a $2.3 million gain from the reversal of a CIRM grant liability.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 59% (from $48.9 million to $20.2 million) year-over-year. This was driven by a 71% reduction in R&D expenses and a 20% reduction in G&A expenses, primarily due to a corporate reorganization in 2025 that included workforce reductions and the discontinuation of several clinical programs (e.g., asthma, SCID, MDS/AML).
- Non-Cash Gains: The net loss improved significantly due to non-cash items: a $13.6 million gain from the decrease in the fair value of warrant liabilities and a $2.3 million gain from the reversal of a CIRM grant liability, as the company determined repayment was no longer probable.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $21.4 million during the six-month period, leaving the company with $7.3 million as of June 30, 2026.
Outlook, Risks, and Subsequent Events
Subsequent Events (Post-June 30, 2026):
- Merger with Kira Pharmaceuticals: On July 16, 2026, Jasper acquired Kira Pharmaceuticals. The transaction involved the issuance of voting common stock and Non-Voting Convertible Preferred Stock to Kira shareholders.
- Financing: Concurrent with the merger, the company completed a private placement financing on July 20, 2026, raising gross proceeds of approximately $132.0 million through the sale of Non-Voting Convertible Preferred Stock.
- Contingent Value Rights (CVRs): Existing shareholders received CVRs entitling them to a pro-rata portion of a $30.0 million payment if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028.
Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the filing date, absent the successful conversion of the new preferred stock or additional financing. If stockholder approval for the conversion of the Non-Voting Convertible Preferred Stock is not obtained within 12 months, holders have the right to require a cash repurchase at fair market value.
Risks: Key risks include the failure to obtain stockholder approval for the preferred stock conversion, the inability to integrate Kira's operations, ongoing litigation (shareholder class action and derivative suits), and the potential delisting from Nasdaq due to the stock price trading below the $1.00 minimum bid price requirement.
Investor Verification Checklist
- Financing Terms: Verify the specific terms of the $132 million Non-Voting Convertible Preferred Stock financing, including the conversion ratio (61:1) and the timeline for the required stockholder vote.
- Going Concern Status: Confirm the company's cash runway post-financing and the likelihood of obtaining stockholder approval to avoid a potential cash repurchase obligation.
- Merger Integration: Assess the progress of the Kira Pharmaceuticals integration and the combined pipeline strategy (KP-104, briquilimab, KP-701).
- Nasdaq Compliance: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Legal Proceedings: Track the status of the shareholder class action lawsuit regarding briquilimab clinical trial disclosures and the related derivative suits.